Methotrexate is under clinical development by Hubei Soundny Bio-Tech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Methotrexate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Methotrexate overview

Methotrexate is under development for the treatment of recrruent and refractory ovarian cancer, malignant pleural effusion and non-small cell lung cancer. The drug candidate is administered as an intrapleural and peritoneal infusion. The drug candidate is based on vesicles technology platform. Methotrexate acts by targeting dihydrofolate reductase (DHF).

Hubei Soundny Bio-Tech overview

Hubei Soundny Bio-Tech is a biotechnology company. Specializing in the research, development, application and promotion of drug-loaded vesicle treatment for cancer technology. It is headquartered in Wuhan, Hubei, China.

For a complete picture of Methotrexate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.